
"I am glad that taking part in a trial might help others on their own cancer journey.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is comparing a new drug called GDC-0980 with everolimus (Afinitor) for kidney cancer that has spread to another part of the body.
The most common type of kidney cancer in adults is renal cell cancer. Doctors can treat kidney cancer with surgery or biological therapy.
Everolimus is a type of biological therapy that doctors use for advanced kidney cancer that has come back either during or after treatment. Everolimus stops a protein called mTOR from working properly. The mTOR protein controls other proteins that trigger cancer cells to grow. By blocking mTOR, everolimus helps stop cancer growing.
GDC-0980 is also a biological therapy. We know from laboratory studies that GDC-0980 may work better at blocking mTOR than everolimus. It also blocks other proteins, such as PI3K, which also trigger cancer cells to grow.
Researchers think that GDC-0980 may be better than everolimus to treat kidney cancer that has spread. In this trial they are comparing the 2 drugs.
The aim of the trial is to find out if GDC-0980 is better than everolimus for treating kidney cancer that has spread.
You may be able to enter this trial if
You cannot enter this trial if you
This is a phase 2 trial. It will recruit 80 people from different countries around the world. It is a randomised trial. You will be put into 1 of 2 treatment groups by a computer. Neither you nor your doctor can choose which group you are in.
GDC-0980 is a tablet. You must take it on an empty stomach. You should not have anything to eat or drink (apart from water) for 2 hours before taking it or for 1 hour afterwards. You take it with at least half a glass of water, about the same time each day.
Everolimus is a tablet. You take it with a glass of water about the same time each day. You can take it with or without food.
You have a diary to record the date and time you take your GDC-0980 or everolimus. You can continue taking your tablets along as the side effects aren’t too bad and they are still helping you.
The trial team will also ask you to give some extra blood samples. For people having GDC-0980, they will take
For people having everolimus, they will take 2 blood samples on the day you start treatment and 1 other sample later on in your treatment. They will use these samples to find out how GDC-0980 and everolimus work in the body.
You see the doctor and have some tests before taking part in this trial. These tests include
During the first 2 months of treatment you see the doctor every 2 weeks and have the following tests
You then see the doctor once a month and have the same tests. You have a CT scan every 2 months. When you finish treatment you see the doctor for the same tests and also have a heart trace. Then you see the doctor every 3 months.
The research team will continue to follow you up for the rest of your life but this can be done over the telephone.
The most common side effects of GDC-0980 include
The most common side effects of everolimus include
You can find more about everolimus in our cancer drugs section.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Prof Thomas Powles
Experimental Cancer Medicine Centre (ECMC)
National Institute for Health Research Cancer Research Network (NCRN)
Roche-Genentech
Freephone 0808 800 4040
"I am glad that taking part in a trial might help others on their own cancer journey.”